Best for
Mobile

Ventas, Inc (VTR) is a leading reit-healthcare facilities business based in the US. Ventas is listed on the NYSE and employs 516 staff. All prices are listed in US Dollars.
Best for
Mobile
Best for
Low-cost
Best for
All rounder
Best for
Beginners
52-week range | $12.5662 - $59.6343 |
---|---|
50-day moving average | $48.7391 |
200-day moving average | $43.7032 |
Wall St. target price | $46.85 |
PE ratio | 54.2274 |
Dividend yield | $1.8 (3.66%) |
Earnings per share (TTM) | $0.906 |
Other fees may apply. Your capital is at risk.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Ventas stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ventas's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ventas's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 54x. In other words, Ventas shares trade at around 54x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Ventas's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 314.9359. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ventas's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ventas's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $1.6 billion.
The EBITDA is a measure of a Ventas's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $3.9 billion |
---|---|
Operating margin TTM | 16.26% |
Gross profit TTM | $2 billion |
Return on assets TTM | 1.6% |
Return on equity TTM | 3.17% |
Profit margin | 8.82% |
Book value | $27.271 |
Market capitalisation | $18.4 billion |
TTM: trailing 12 months
There are currently 8.5 million Ventas shares held short by investors – that's known as Ventas's "short interest". This figure is 3.7% up from 8.2 million last month.
There are a few different ways that this level of interest in shorting Ventas shares can be evaluated.
Ventas's "short interest ratio" (SIR) is the quantity of Ventas shares currently shorted divided by the average quantity of Ventas shares traded daily (recently around 2.1 million). Ventas's SIR currently stands at 4.1. In other words for every 100,000 Ventas shares traded daily on the market, roughly 4100 shares are currently held short.
However Ventas's short interest can also be evaluated against the total number of Ventas shares, or, against the total number of tradable Ventas shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ventas's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Ventas shares in existence, roughly 20 shares are currently held short) or 0.0295% of the tradable shares (for every 100,000 tradable Ventas shares, roughly 30 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ventas.
Find out more about how you can short Ventas stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Ventas.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 21.31
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Ventas's overall score of 21.31 (as at 01/01/2019) is excellent – landing it in it in the 13rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Ventas is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 8.8/100
Ventas's environmental score of 8.8 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Ventas is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 9.95/100
Ventas's social score of 9.95 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Ventas is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 9.56/100
Ventas's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Ventas is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Ventas, Inc was last rated for ESG on: 2019-01-01.
Total ESG score | 21.31 |
---|---|
Total ESG percentile | 12.96 |
Environmental score | 8.8 |
Environmental score percentile | 8 |
Social score | 9.95 |
Social score percentile | 8 |
Governance score | 9.56 |
Governance score percentile | 8 |
Dividend payout ratio: 55.99% of net profits
Recently Ventas has paid out, on average, around 55.99% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.66% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Ventas shareholders could enjoy a 3.66% return on their shares, in the form of dividend payments. In Ventas's case, that would currently equate to about $1.8 per share.
Ventas's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Ventas's most recent dividend payout was on 20 January 2021. The latest dividend was paid out to all shareholders who bought their shares by 31 December 2020 (the "ex-dividend date").
Ventas's shares were split on a 8757:10000 basis on 18 August 2015. So if you had owned 10000 shares the day before before the split, the next day you'd have owned 8757 shares. This wouldn't directly have changed the overall worth of your Ventas shares – just the quantity. However, indirectly, the new 14.2% higher share price could have impacted the market appetite for Ventas shares which in turn could have impacted Ventas's share price.
Over the last 12 months, Ventas's shares have ranged in value from as little as $12.5662 up to $59.6343. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Ventas's is 1.2815. This would suggest that Ventas's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Subscribe to trending stock alerts for a chance to win
Ventas, an S&P 500 company, operates at the intersection of two powerful and dynamic industries ? healthcare and real estate. As one of the world's foremost Real Estate Investment Trusts (REIT), we use the power of capital to unlock the value of real estate, partnering with leading care providers, developers, research and medical institutions, innovators and healthcare organizations whose success is buoyed by the demographic tailwind of an aging population. For more than twenty years, Ventas has followed a successful strategy that endures: combining a high-quality diversified portfolio of properties and capital sources to manage through cycles, working with industry leading partners, and a collaborative and experienced team focused on producing consistent growing cash flows and superior returns on a strong balance sheet, ultimately rewarding Ventas shareholders. As of September 30, 2020, Ventas owned or managed through unconsolidated joint ventures approximately 1,200 properties.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.